Covid-19 Relaunch Information

On May 14th, 2020 – Alberta’s Chief Medical Officer announced the start of Stage 1.


As part of the Stage 1 re-opening strategy, We will be resuming in person sessions to anyone who is healthy, who has not been exposed to someone with Covid-19 symptoms and has not travelled outside of Canada within the 14 days prior to their scheduled appointment

Please note that although the office has now reopened, SecureVideo sessions are still being offered to clients who prefer having the additional safety of online sessions.

The following precautions will be taken to ensure your safety in the office:

  • Before attending an appointment we ask that all clients complete a brief screening assessment.
  • At the start of each day, we will also be taking a self screening assessment.
  • Physical distancing requirements have been met in all individual therapy offices and waiting areas by reconfiguring the seating.
  • High contact surfaces such as doorknobs, credit machines, couches, tables, and chairs will be disinfected after each in-person session.
  • Please feel free to request that we wear a face mask or use plexiglass between our chairs during our session.
  • Sessions with children will require face masks for both parties as we’ll be in close proximity to each other. Please feel free to request us to additionally wear a face shield.

Upon arrival for your session, please observe the following safety measures:

  • A confirmation email will be sent to you with screening criteria. Please let us know as soon as possible of any concerns.
  • Please do not arrive more than 5 minutes early for your scheduled appointment.
  • Wash hands and or use sanitizer upon arriving for your appointment.
  • Remember to avoid touching your face as much as possible, especially your eyes, nose, and mouth with unwashed hands and re-sanitize hands as needed.  
  • Cover all coughs and sneezes.

Please request an online session and stay home to keep others safe if you are experiencing any symptoms related to Covid-19.